Expression of β 1 Integrins (Very Late Antigens-4 and −5) on Myeloma Cells and Clinical Correlates in Patients with Multiple Myeloma

Abstract

β₁ Integrins are considered to be essential for the differentiation of bone-marrow B cells through an interaction with fibronectin-expressed bone-marrow stromal cells. The expression of very late antigens-4 (VLA-4) and −5 (VLA-5) by CD38^bright bone-marrow cells in patients with multiple myeloma was measured by flow cytometry using specific monoclonal antibodies. The percentage of CD38^bright bone-marrow cells appeared to correlate with that of bone-marrow plasma cells as judged by examination of bone-marrow smears (r = 0.911, P < 0.0001). Expression of VLA-4 and VLA-5 by CD38^bright cells varied between patients, but the expression of VLA-4 was always equal to or greater than that of VLA-5. The ratio of VLA-4 to VLA-5 expression (VLA-4:VLA-5 ratio) was calculated and compared with the clinical features of the myeloma patients. A high VLA-4: VLA-5 ratio (> 2.0) was associated with the presence of plasmacytomas and urinary Bence-Jones protein was more common in this group. No other correlations between the clinical features of the disease and the expression of β₁ integrins were found.

Keywords

Multiple myeloma Plasmacytoma Very Late Antigen-4 Very Late Antigen-5 Bence-Jones Protein

Get full access to this article

View all access options for this article.

References

Durie

BGM

Salmon

A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36: 842–854.

San Miguel

Gonzalez

Gascon

Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Br J Haematol 1991; 77: 185–190.

Van Camp

Durie

Spier

Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu19). Blood 1990; 76: 377–382.

Ruiz-Arguelles

San Miguel

Cell surface markers in multiple myeloma. Mayo Clin Proc 1994; 69: 684–690.

Leo

Boeker

Peest

Multiparameter analysis of normal and malignant human plasma cell: CD38++, CD56+, CD54+, cIg+, is the common phenotype of myeloma cells. Ann Hematol 1992; 64: 132–139.

Kawano

Huang

Harada

Identification of immature and mature myeloma cells in the bone marrow of human myeloma. Blood 1993; 82: 564–570.

Hamilton

Ball

Bromidge

Surface antigen expression of human neoplastic plasma cells includes molecules associated with lymphocyte recirculation and adhesion. Br J Haematol 1991; 78: 60–65.

Van Riet

De Waele

Remels

Expression of cyto-adhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells. Br J Haematol 1991; 79: 421–427.

Ahsmann

EJM

Lokhorst

Dekker

Lymphocyte function-associated antigen-1 expression on plasma cells correlates with tumor growth in multiple myeloma. Blood 1992; 79: 2068–2075.

10.

Huang

Kawano

Harada

Heterogeneous expression of a novel MPC-1 antigen on myeloma cells: possible involvement of MPC-1 antigen in adhesion of mature myeloma cells to bone marrow stromal cells. Blood 1993; 82: 3721–3729.

11.

Suchman

Coleman

Mouradian

Aggressive plasma cell myeloma: a terminal phase. Arch Intern Med 1981; 141: 1315–1320.

12.

Falini

De Solas

Levine

Emergence of B-immunoblastic sarcoma in patients with multiple myeloma; clinicopathological study of 10 cases. Blood 1982; 59: 923–933.

13.

Pilarski

Jensen

Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules. Hematol Oncol Clin North Am 1992; 6: 297–322.

14.

Bernardi

Patel

Lodish

Lymphoid precursor cells adhere to two distinct sites on fibronectin. J Cell Biol 1987; 105: 489–498.

15.

Guan

J-L

Hynes

Lymphoid cells recognize an alternatively spliced segment of fibronectin via the integrin receptor α₄ β₁

Cell 1990; 60: 53–61.